Inactive Instrument

Press Releases Roche Holding Ltd. Swiss Exchange

Equities

CH0012032048

Real-time Estimate Cboe Europe Other stock markets 11:08:10 2024-05-10 EDT
225.4 ^CHF	0.00%

02:43pm	Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	MT
05-07	Enable Injections, Inc. Announces Collaboration with Roche to Develop and Commercialize Combination of the enFuse Technology with Specific Roche Development Programs	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	04-18	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	04-17	BU
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	04-15	BU
Invitation to Roche's First Quarter Sales 2024 Presentation	03-25	AQ
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024	03-12	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	03-06	AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	02-25	BU
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	02-19	AQ
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	02-16	BU
AlzeCure Pharma broadcasts live expert event on Alzheimer's around highly current gamma-secretase modulators	02-12	AQ
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	02-01	AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)	02-01	BU
Prolight`s CEO to BioStock: "Roche's acquisition highlights interest in Point-of-Care"	01-29	AQ
Reminder, Invitation to Roche's Full Year Results 2023 Presentation	01-26	AQ
LINEAGE CELL - RG6501 PHASE 1/2A RESULTS WILL BE FEATURED AT 2024 ANGIOGENESIS EXUDATION AND DEGENERATION MEETING IN PRESENTATION BY ALLEN HO, MD, FACS, FASRS	01-17	AQ
Roche cancer immunotherapy receives new EU approval	01-16	AQ
Inotrem successfully reaches agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock	01-09	AQ
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit	01-09	AQ
Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI	01-08	AQ
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform	01-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am